[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 34 of about 34
1. Bramwell V: When to consider adjuvant/neoadjuvant therapy for adult soft-tissue sarcoma. Oncology (Williston Park); 2007 Apr;21(4):511-4
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] When to consider adjuvant/neoadjuvant therapy for adult soft-tissue sarcoma.
  • In patients with adult soft-tissue sarcoma (ASTS), the use and timing of adjuvant chemotherapy or chemoradiotherapy remains controversial.
  • The appropriate target population is generally accepted as International Union Against Cancer (UICC)/American Joint Committee on Cancer (AJCC) stage III extremity or trunk sarcomas (i.e., >5 cm, grade 3/4, located deep to the superficial fascia, with no evidence of metastases).
  • [MeSH-major] Neoadjuvant Therapy. Neoplasm Recurrence, Local. Sarcoma / drug therapy. Sarcoma / radiotherapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Humans. Meta-Analysis as Topic. Randomized Controlled Trials as Topic. Retrospective Studies

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17474349.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Congresses
  • [Publication-country] United States
  •  go-up   go-down


2. Latt LD, Turcotte RE, Isler MH, Wong C: Case series. Soft-tissue sarcoma of the foot. Can J Surg; 2010 Dec;53(6):424-31
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case series. Soft-tissue sarcoma of the foot.
  • BACKGROUND: We reviewed cases of soft-tissue sarcoma of the foot to gain insight into the presentation, treatments and outcomes for this rare disease and to determine whether limb-salvage surgery yields reasonable functional and oncological outcomes.
  • METHODS: We reviewed the cases of 16 patients treated by 2 of us (R.T. and M.I.) for soft-tissue sarcoma of the foot over a 15-year period.
  • We extracted the following information from each patient's medical record: disease status at presentation, prior treatment, histological diagnosis, American Joint Committee on Cancer (AJCC) stage, details of treatment, oncological outcome and functional outcome.
  • Histological diagnosis was synovial sarcoma for 7 of 16 patients.The tumours were evenly distributed among the hindfoot, midfoot and forefoot.
  • Most patients (n = 13) presented with AJCC stage II or III disease.
  • Free tissue transfer (n = 9) and radiation therapy (n = 12) were used in most cases.
  • Second, limb salvage was usually possible, but it required accepting marginal resections, relying on free tissue transfer to obtain coverage and using radiation therapy to obtain local control.
  • [MeSH-major] Foot / surgery. Sarcoma / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Amputation / statistics & numerical data. Female. Follow-Up Studies. Free Tissue Flaps / statistics & numerical data. Humans. Limb Salvage / statistics & numerical data. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Radiotherapy, Adjuvant / statistics & numerical data

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Foot Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2000 Apr;36(6):710-6 [10762742.001]
  • [Cites] Foot Ankle Int. 2008 Jul;29(7):690-8 [18785419.001]
  • [Cites] Eur J Surg Oncol. 2000 Nov;26(7):679-85 [11078615.001]
  • [Cites] Acta Orthop Scand. 2000 Oct;71(5):488-95 [11186407.001]
  • [Cites] J Bone Joint Surg Br. 2001 Nov;83(8):1149-55 [11764430.001]
  • [Cites] Ann Surg. 2002 Mar;235(3):424-34 [11882765.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2235-41 [12103287.001]
  • [Cites] J Orthop Surg (Hong Kong). 2002 Dec;10(2):173-8 [12493931.001]
  • [Cites] Cancer. 2003 Jan 15;97(2):485-92 [12518373.001]
  • [Cites] Ann Surg Oncol. 2004 May;11(5):476-82 [15078635.001]
  • [Cites] J Clin Oncol. 1985 Oct;3(10):1344-8 [4045526.001]
  • [Cites] Semin Oncol. 1989 Aug;16(4):289-96 [2667143.001]
  • [Cites] J Bone Joint Surg Br. 1993 Jul;75(4):658-60 [8331127.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1652-9 [8156492.001]
  • [Cites] Acta Orthop Scand Suppl. 1994 Jun;259:1-31 [8042499.001]
  • [Cites] Acta Orthop Scand. 1994 Oct;65(5):553-8 [7801762.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1679-89 [8622088.001]
  • [Cites] Qual Life Res. 1996 Oct;5(5):508-16 [8973131.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):646-52 [9053489.001]
  • [Cites] J Pediatr Surg. 1997 Aug;32(8):1181-4 [9269966.001]
  • [Cites] J Surg Oncol. 1997 Oct;66(2):81-7 [9354161.001]
  • [Cites] Arch Phys Med Rehabil. 1999 Jun;80(6):615-8 [10378484.001]
  • [Cites] Ann Surg Oncol. 2005 Jan;12(1):10-7 [15827772.001]
  • [Cites] Radiother Oncol. 2005 Apr;75(1):48-53 [15948265.001]
  • [Cites] Am J Clin Oncol. 2006 Feb;29(1):62-5 [16462505.001]
  • [Cites] J Surg Oncol. 2000 Apr;73(4):206-11 [10797333.001]
  • (PMID = 21092437.001).
  • [ISSN] 1488-2310
  • [Journal-full-title] Canadian journal of surgery. Journal canadien de chirurgie
  • [ISO-abbreviation] Can J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2993038
  •  go-up   go-down


3. Takeuchi A, Tsuchiya H, Yamamoto N, Hayashi K, Yamauchi K, Kawahara M, Miyamoto K, Tomita K: Caffeine-potentiated chemotherapy for patients with high-grade soft tissue sarcoma: long-term clinical outcome. Anticancer Res; 2007 Sep-Oct;27(5B):3489-95
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caffeine-potentiated chemotherapy for patients with high-grade soft tissue sarcoma: long-term clinical outcome.
  • The present study was performed to assess the efficacy of caffeine-potentiated chemotherapy for high-grade soft tissue sarcoma (STS).
  • PATIENTS AND METHODS: A non-randomised prospective clinical trial was initiated for 90 patients with non-metastatic (stages II and III) or metastatic (stage IV) STS.
  • The local recurrence rate was 23.7% in stages II and III and 13.6% in stage IV.
  • Lung metastases newly developed in 21 (35.6%) patients at stages II and III.
  • With a median follow-up period of 52 months, the overall 5-year cumulative survival rate at stages II and III was 80.7%.
  • Local recurrence-free survival for the histological responders and distant metastasis-free survival for the radiographic responders at stages II and III were significantly improved compared to the non-responders (p=0.004 and p=0.034).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Caffeine / therapeutic use. Sarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Disease-Free Survival. Drug Synergism. Female. Humans. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Preoperative Care. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Caffeine.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. CAFFEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17972506.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 3G6A5W338E / Caffeine
  •  go-up   go-down


Advertisement
4. Cahlon O, Spierer M, Brennan MF, Singer S, Alektiar KM: Long-term outcomes in extremity soft tissue sarcoma after a pathologically negative re-resection and without radiotherapy. Cancer; 2008 Jun 15;112(12):2774-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes in extremity soft tissue sarcoma after a pathologically negative re-resection and without radiotherapy.
  • BACKGROUND: The purpose was to define the rate of local recurrence (LR) and identify prognostic factors for LR in patients with extremity soft-tissue sarcoma (STS) treated with limb-sparing surgery and a pathologically negative re-resection specimen without radiotherapy (RT).
  • METHODS: A review of the prospective sarcoma database identified 200 patients with primary, nonmetastatic, extremity STS treated with limb-sparing surgery between June 1982 and December 2002 who had a pathologically confirmed negative re-resection.
  • Factors associated with higher LR rates on univariate and multivariate analysis were older age, stage III presentation, and histology.
  • For patients with stage III the LR rate was 26% versus 7% for those with stage I/II (P<.001).
  • On multivariate analysis only age>or=50 (relative risk [RR] 3.3; P=.02) and stage III disease (RR 3.4; P=.01) remained significant predictors for LR.
  • When the cohort of patients was divided into 3 groups based on the number of risk factors present, the 5-year LRs were as follows: no risk factors (stage I/II and<50 years old) 4%, 1 risk factor (stage III or>or=50) 12%, and 2 risk factors (stage III and>or=50) 31% (P<.01).
  • Whereas the overall rate of local recurrence at 5 years was 9% for the entire cohort, patients with older age and/or stage III disease had a higher rate of LR.
  • [MeSH-major] Extremities / surgery. Neoplasm Recurrence, Local / pathology. Sarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Disease-Free Survival. Feasibility Studies. Humans. Middle Aged. Radiotherapy, Adjuvant. Reoperation. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 American Cancer Society.
  • (PMID = 18429001.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Novais EN, Demiralp B, Alderete J, Larson MC, Rose PS, Sim FH: Do surgical margin and local recurrence influence survival in soft tissue sarcomas? Clin Orthop Relat Res; 2010 Nov;468(11):3003-11
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do surgical margin and local recurrence influence survival in soft tissue sarcomas?
  • BACKGROUND: Established prognostic factors influencing survival in soft tissue sarcomas include tumor stage, histopathologic grade, size, depth, and anatomic site.
  • QUESTIONS/PURPOSES: We explored the impact of microscopic margin on local recurrence, metastasis, and overall survival in patients with intermediate- to high-grade soft tissue sarcomas of the extremities.
  • METHODS: We retrospectively reviewed the medical records of 248 patients who had soft tissue sarcomas of the extremities treated surgically from 1995 to 2008.
  • In addition to surgical margin, developing metastasis, tumor response of less than 90% necrosis, high histopathologic grade, high AJCC stage (Stage III), increasing age, and male gender were associated with decreased overall survival.
  • CONCLUSIONS: Microscopic surgical margin and local recurrence after surgical treatment should be included as risk factors predicting decreased overall survival for intermediate- to high-grade soft tissue sarcomas of the extremities.
  • [MeSH-major] Neoplasm Recurrence, Local / mortality. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Extremities. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Minnesota / epidemiology. Neoplasm Staging. Proportional Hazards Models. Registries. Retrospective Studies. Risk Assessment. Risk Factors. Survival Rate. Time Factors. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2000 Apr;36(6):710-6 [10762742.001]
  • [Cites] Ann Surg. 2003 Feb;237(2):218-26 [12560780.001]
  • [Cites] Acta Orthop Scand Suppl. 2001 Feb;72(300):1-31 [11381580.001]
  • [Cites] Ann Surg. 1982 Sep;196(3):305-15 [7114936.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5):526-33 [9344318.001]
  • [Cites] J Surg Oncol. 1997 Oct;66(2):81-7 [9354161.001]
  • [Cites] Arch Surg. 1999 Feb;134(2):190-4 [10025462.001]
  • [Cites] Aust N Z J Surg. 1999 May;69(5):344-9 [10353548.001]
  • [Cites] Semin Radiat Oncol. 1999 Oct;9(4):307-14 [10516378.001]
  • [Cites] Semin Radiat Oncol. 1999 Oct;9(4):369-77 [10516384.001]
  • [Cites] ANZ J Surg. 2006 Mar;76(3):104-9 [16626341.001]
  • [Cites] Ann Surg Oncol. 2007 May;14(5):1583-90 [17260106.001]
  • [Cites] Ann Surg Oncol. 2007 May;14(5):1528-9 [17295083.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] J Clin Oncol. 1983 Nov;1(11):710-9 [6668489.001]
  • [Cites] Ann Surg. 1987 Apr;205(4):331-9 [3566371.001]
  • [Cites] Arch Surg. 1987 Nov;122(11):1289-93 [3314794.001]
  • [Cites] Semin Surg Oncol. 1988;4(1):38-44 [2832924.001]
  • [Cites] J Clin Oncol. 1988 Sep;6(9):1491-500 [3047339.001]
  • [Cites] J Clin Oncol. 1992 Aug;10(8):1317-29 [1634922.001]
  • [Cites] Clin Orthop Relat Res. 1993 Apr;(289):73-80 [8472434.001]
  • [Cites] Cancer. 1993 Aug 15;72(4):1230-8 [8339214.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1652-9 [8156492.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1679-89 [8622088.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):646-52 [9053489.001]
  • [Cites] J Bone Joint Surg Br. 1997 Jul;79(4):553-7 [9250737.001]
  • [Cites] Clin Orthop Relat Res. 2001 Jun;(387):191-9 [11400883.001]
  • [Cites] J Bone Joint Surg Br. 2001 Nov;83(8):1149-55 [11764430.001]
  • [Cites] Ann Surg. 2002 Mar;235(3):424-34 [11882765.001]
  • [Cites] Acta Orthop Scand. 2000 Oct;71(5):488-95 [11186407.001]
  • (PMID = 20645035.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2947688
  •  go-up   go-down


6. Al-Refaie WB, Andtbacka RH, Ensor J, Pisters PW, Ellis TL, Shrout A, Hunt KK, Cormier JN, Pollock RE, Feig BW: Lymphadenectomy for isolated lymph node metastasis from extremity soft-tissue sarcomas. Cancer; 2008 Apr 15;112(8):1821-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphadenectomy for isolated lymph node metastasis from extremity soft-tissue sarcomas.
  • BACKGROUND: Previous studies have suggested that the prognosis in patients with extremity soft-tissue sarcomas (ESTS) with isolated lymph node (LN) metastases (stage IV) is comparable to that of patients with high-risk ESTS without metastases (stage III).
  • Survival after the diagnosis of primary disease and LN metastasis was compared with established historical outcomes for patients with American Joint Commission on Cancer (AJCC) stages III and IV ESTS.
  • CONCLUSIONS: Patients with isolated regional lymph node metastases who are treated with aggressive approaches, including regional LN dissection, may experience prolonged survival similar to that which more closely approximates the survival seen in patients with stage III disease (5-year survival rate, 50%) rather than the survival seen in patients with stage IV disease (5-year survival rate, 25%).
  • [MeSH-major] Lower Extremity / pathology. Lymph Node Excision / methods. Lymphatic Metastasis / pathology. Sarcoma / secondary. Soft Tissue Neoplasms / secondary. Upper Extremity / pathology
  • [MeSH-minor] Actuarial Analysis. Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Histiocytoma, Malignant Fibrous / secondary. Histiocytoma, Malignant Fibrous / surgery. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18306370.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Oda Y, Saito T, Tateishi N, Ohishi Y, Tamiya S, Yamamoto H, Yokoyama R, Uchiumi T, Iwamoto Y, Kuwano M, Tsuneyoshi M: ATP-binding cassette superfamily transporter gene expression in human soft tissue sarcomas. Int J Cancer; 2005 May 10;114(6):854-62
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ATP-binding cassette superfamily transporter gene expression in human soft tissue sarcomas.
  • However, their expression levels and distribution within soft tissue sarcomas remain controversial.
  • In 86 cases of surgically resected soft tissue sarcoma, intrinsic mRNA levels of MDR1, MRP1, MRP2 and MRP3 were assessed using a quantitative reverse transcriptase-PCR (RT-PCR) method.
  • P-gp expression was significantly correlated with large tumor size (> or =5 cm, p=0.041) and high AJCC stage (stages III and IV) (p=0.0365).
  • Our results suggest that MDR1/P-gp expression may have an important role to play in tumor progression in the cases of soft tissue sarcoma, and p53 may be one of the active regulators of the MDR1 transcript.
  • [MeSH-major] ATP-Binding Cassette Transporters / biosynthesis. ATP-Binding Cassette Transporters / genetics. Drug Resistance, Multiple. Gene Expression Regulation, Neoplastic. Genes, p53. Sarcoma / drug therapy. Sarcoma / genetics
  • [MeSH-minor] Adolescent. Adult. Disease Progression. Drug Resistance, Neoplasm / genetics. Female. Gene Expression Profiling. Humans. Immunohistochemistry. Male. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15609299.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


8. Papanastassiou I, Ioannou M, Magoulas D, Lalos S, Athanassiou AE, Ziras N, Thanopoulou E, Demertzis N: Chemoembolization facilitates limb salvage surgery in stage III soft tissue sarcoma. J BUON; 2009 Jul-Sep;14(3):507-10
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoembolization facilitates limb salvage surgery in stage III soft tissue sarcoma.
  • A 26 year-old male was referred to our unit because of a stage III soft tissue sarcoma in the shoulder girdle-axillary area and reduced forearm-distal arm strength.
  • In stage III soft tissue sarcomas, especially in proximity with major nerve/arterial bundles, a multimodality approach is mandatory; chemoembolization is very effective in shrinking the tumor and defining its margins so as to make feasible a LSS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Embolization, Therapeutic. Limb Salvage. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Chemotherapy, Adjuvant. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Humans. Male. Neoplasm Staging. Radiotherapy, Adjuvant. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19810146.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


9. Lahat G, Tuvin D, Wei C, Anaya DA, Bekele BN, Lazar AJ, Pisters PW, Lev D, Pollock RE: New perspectives for staging and prognosis in soft tissue sarcoma. Ann Surg Oncol; 2008 Oct;15(10):2739-48
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New perspectives for staging and prognosis in soft tissue sarcoma.
  • BACKGROUND: Data suggest that the current American Joint Committee on Cancer (AJCC) soft tissue sarcoma (STS) staging criteria merit further evaluation.
  • METHODS: Prospectively accrued data were analyzed for 1,091 AJCC stage I to III primary STS patients who had complete macroscopic resection at our institution from 1996 to 2007.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Sarcoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cohort Studies. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2008 Oct;15(10):2643 [18685895.001]
  • (PMID = 18521685.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. Jakob J, Wenz F, Dinter DJ, Ströbel P, Hohenberger P: Preoperative intensity-modulated radiotherapy combined with temozolomide for locally advanced soft-tissue sarcoma. Int J Radiat Oncol Biol Phys; 2009 Nov 1;75(3):810-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative intensity-modulated radiotherapy combined with temozolomide for locally advanced soft-tissue sarcoma.
  • PURPOSE: To evaluate the toxicity and efficacy of preoperative intensity-modulated radiotherapy (IMRT) combined with temozolomide to improve local tumor control in soft-tissue sarcoma (STS).
  • PATIENTS AND METHODS: A cohort of 15 consecutive patients with nonmetastasized, primary high-grade or locally recurrent Stage III (n = 14) or IIb (n = 1) STS not amenable to surgical resection without significant organ or extremity function loss was prospectively investigated.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Dacarbazine / analogs & derivatives. Radiotherapy, Intensity-Modulated. Sarcoma
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy / adverse effects. Combined Modality Therapy / methods. Female. Humans. Male. Middle Aged. Nausea / etiology. Postoperative Complications. Prospective Studies. Radiation Injuries / etiology. Radiotherapy Dosage. Remission Induction. Tumor Burden. Vomiting / etiology

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19307066.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


11. Manoso MW, Frassica DA, Deune EG, Frassica FJ: Outcomes of re-excision after unplanned excisions of soft-tissue sarcomas. J Surg Oncol; 2005 Sep 1;91(3):153-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of re-excision after unplanned excisions of soft-tissue sarcomas.
  • BACKGROUND AND OBJECTIVES: Unplanned excisions of soft-tissue sarcomas of the extremities occur commonly.
  • Our goal was to evaluate the presence of residual disease, the treatment outcomes as they relate to local and distant recurrence and 5-year survival, and the limb functional outcomes in patients with unplanned sarcoma excision who were treated with re-excision and adjuvant therapy.
  • METHODS: Between 1993 and 1999, 42 patients presented to our institution after unplanned excision of soft-tissue sarcomas.
  • Univariate analysis showed that stage-III disease (American Joint Committee on Cancer classification of soft-tissue sarcomas), lesions below the fascia, a histologic high-grade, and the development of organ metastasis were statistically significant factors for mortality.
  • Stage-III disease also was significant for mortality on multivariate analysis.
  • Only stage-III disease was significant for the development of local recurrence.
  • [MeSH-major] Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Baltimore / epidemiology. Combined Modality Therapy. Female. Humans. Logistic Models. Male. Middle Aged. Multivariate Analysis. Proportional Hazards Models. Reoperation. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16118773.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Wang L, Tan MH: The natural history and prognosticative factors of adult extremity soft tissue sarcomas: an Asian perspective. Ann Acad Med Singapore; 2010 Oct;39(10):771-7
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The natural history and prognosticative factors of adult extremity soft tissue sarcomas: an Asian perspective.
  • INTRODUCTION: We describe the natural history of Asian adult soft tissue sarcomas (STSs) in the extremities and predict prognosticative factors for local recurrence, metastasis and tumour-related death.
  • MATERIALS AND METHODS: Between January 1999 and May 2009, 67 adult patients with first presentation STSs of extremity sites underwent surgical treatment at a single institution.
  • Stages Ia, Ib, IIa, IIb, IIc, III and IV accounted for 6.6%, 6.6%, 26.2%, 11.5%, 3.3%, 42.6% and 3.3% of presentations, respectively.
  • On univariate analysis, high tumour grade and advanced stage (IIc to IV) were predictive of local recurrence and metastasis.
  • CONCLUSIONS: Asian adult extremity soft tissue sarcomas present late and are most commonly found in the thigh.
  • [MeSH-major] Extremities / physiopathology. Sarcoma. Soft Tissue Neoplasms
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Asia / epidemiology. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21063637.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


13. Kim B, Chen YL, Kirsch DG, Goldberg SI, Kobayashi W, Kung JH, Wolfgang JA, Doppke K, Rosenberg AE, Nielsen GP, Raskin KA, Springfield DS, Schwab JH, Gebhardt MC, Yoon SS, Hornicek FJ, DeLaney TF: An effective preoperative three-dimensional radiotherapy target volume for extremity soft tissue sarcoma and the effect of margin width on local control. Int J Radiat Oncol Biol Phys; 2010 Jul 1;77(3):843-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An effective preoperative three-dimensional radiotherapy target volume for extremity soft tissue sarcoma and the effect of margin width on local control.
  • PURPOSE: There is little information on the appropriate three-dimensional (3D) preoperative radiotherapy (XRT) volume for extremity soft-tissue sarcomas (STS).
  • METHODS AND MATERIALS: We analyzed the 56 patients who underwent computed tomography-planned XRT for Stage I to III extremity STS between June 2000 and December 2006.
  • [MeSH-major] Extremities. Sarcoma / radiotherapy. Soft Tissue Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Analysis of Variance. Female. Humans. Male. Middle Aged. Postoperative Complications / surgery. Preoperative Care. Radiotherapy Dosage. Treatment Failure. Tumor Burden / radiation effects. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20005638.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Sun L, Wu LY, Li XG, Bai P, Zhang HT: [Clinical characterization of vulvar epithelioid sarcoma]. Zhonghua Zhong Liu Za Zhi; 2010 Dec;32(12):935-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characterization of vulvar epithelioid sarcoma].
  • OBJECTIVE: Vulvar epithelioid sarcoma is a rare, undifferentiated soft-tissue sarcoma, with a high rate of local relapse, regional nodal spread and distant metastases.
  • METHODS: We studied the clinicopathologic features of 20 cases of vulvar epithelioid sarcoma, of which 4 cases were admitted to our hospital from 1999 to 2009.
  • Survival of the early stage (I-II) patients was significantly longer than those in the advanced stage (III-IV) (median, 21 vs. 6 months, P < 0.01).
  • Radical local excision with adequate margin (at least 2 cm) and bilateral inguinofemoral lymphadenectomy is effective for the treatment of vulvar epithelioid sarcoma.
  • [MeSH-major] Sarcoma / pathology. Sarcoma / surgery. Soft Tissue Neoplasms / pathology. Soft Tissue Neoplasms / surgery. Vulvar Neoplasms / pathology. Vulvar Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Keratins / metabolism. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Mucin-1 / metabolism. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Vimentin / metabolism. Vulva / surgery. Young Adult


15. Tanaka K, Kawamoto H, Saito I, Yoshimura K, Fukuda H, Iwamoto Y: Preoperative and postoperative chemotherapy with ifosfamide and adriamycin for adult high-grade soft-tissue sarcomas in the extremities: Japan Clinical Oncology Group Study JCOG0304. Jpn J Clin Oncol; 2009 Apr;39(4):271-3
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative and postoperative chemotherapy with ifosfamide and adriamycin for adult high-grade soft-tissue sarcomas in the extremities: Japan Clinical Oncology Group Study JCOG0304.
  • This phase II clinical trial aims to evaluate the efficacies and toxicities of pre- and postoperative chemotherapy with adriamycin plus ifosfamide on the patients with soft-tissue high-grade sarcomas.
  • Patients who have operable, non-round cell soft-tissue sarcomas [French Federation of Cancer Center (FNCLCC) Grades 2 and 3] arising in the extremities [T2bN0M0, i.e.
  • American Joint Committee on Cancer (AJCC) stage III] are treated by three courses of preoperative chemotherapy consisting of adriamycin and ifosfamide followed by complete resection and additional two courses of the same chemotherapy regimen.
  • The Bone and Soft Tissue Tumor Study Group (BSTTSG) in the Japan Clinical Oncology Group (JCOG) including 26 specialized institutes will accrue 75 patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / administration & dosage. Ifosfamide / administration & dosage. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Disease-Free Survival. Extremities. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Neoplasm Staging. Postoperative Care. Preoperative Care

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19155282.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


16. Mu JW, Xing XZ, Li J, Cheng GY, Sun KL, He J: [Primary soft tissue sarcomas of mediastinum: experience in 22 cases from a single institution]. Zhonghua Yi Xue Za Zhi; 2008 Feb 19;88(7):468-70
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary soft tissue sarcomas of mediastinum: experience in 22 cases from a single institution].
  • OBJECTIVE: To assess the presentation, imaging features, and prognostic factors of primary soft tissue sarcoma of mediastinum.
  • METHODS: The clinical data of 22 patients with primary soft tissue sarcoma of mediastinum, 12 males and 10 females, aged 46 (28-69), hospitalized over 27 years were retrospectively reviewed, focusing on the clinical presentations, preoperative diagnosis, imaging features, immunohistochemical studies, treatment, and survival.
  • The 5-year survival rate of the patients with lesions at high grade and stage III were 38.2% and 38.2% respectively, both lower, though not significantly, than those of lesions at low grade and stage I (60% and 60% respectively, both P =0.317).
  • CONCLUSION: Tumor size and character of resection are important prognostic factors for primary soft tissue sarcoma of mediastinum.
  • [MeSH-major] Mediastinal Neoplasms / surgery. Sarcoma / surgery
  • [MeSH-minor] Adult. Aged. Antigens, CD / analysis. Antigens, Differentiation, Myelomonocytic / analysis. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Mediastinum / pathology. Mediastinum / surgery. Middle Aged. Retrospective Studies. Survival Analysis. Vimentin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18642788.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / Vimentin
  •  go-up   go-down


17. MacDermed DM, Miller LL, Peabody TD, Simon MA, Luu HH, Haydon RC, Montag AG, Undevia SD, Connell PP: Primary tumor necrosis predicts distant control in locally advanced soft-tissue sarcomas after preoperative concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys; 2010 Mar 15;76(4):1147-53
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary tumor necrosis predicts distant control in locally advanced soft-tissue sarcomas after preoperative concurrent chemoradiotherapy.
  • PURPOSE: Various neoadjuvant approaches have been evaluated for the treatment of locally advanced soft-tissue sarcomas.
  • METHODS AND MATERIALS: We treated 34 patients (28 Stage III and 6 Stage IV) with locally advanced soft-tissue sarcomas of an extremity between 1995 and 2008.
  • The 5-year survival rate was 42.3% for all patients and 45.2% for Stage III patients.
  • The 5-year freedom-from-distant metastasis rate was 53.4% (Stage IV patients excluded), and freedom from distant metastasis was superior if treatment-induced tumor necrosis was 90% or greater (84.6% vs. 19.9%, p = 0.02).

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [Cites] Cancer. 1993 Jun 1;71(11):3685-9 [8490918.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Sep 30;27(2):259-65 [8407399.001]
  • [Cites] Cancer. 1986 Jan 1;57(1):172-7 [3940616.001]
  • [Cites] Cancer. 1985 Jun 1;55(11):2659-67 [3995476.001]
  • [Cites] Cancer. 1984 Jun 15;53(12):2579-84 [6372980.001]
  • [Cites] Ann Surg. 1982 Sep;196(3):305-15 [7114936.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Eur J Surg Oncol. 2003 Dec;29(10):908-15 [14624787.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1117-27 [12829150.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2235-41 [12103287.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3203-9 [11432887.001]
  • [Cites] Eur J Cancer. 2001 Jun;37(9):1096-103 [11378339.001]
  • [Cites] Cancer. 2001 May 15;91(10):1914-26 [11346874.001]
  • [Cites] Cancer. 1995 May 1;75(9):2299-306 [7712441.001]
  • [Cites] Cancer. 2008 Jun;112(11):2432-9 [18348295.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3144-50 [17634494.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):619-25 [16446334.001]
  • [Cites] Ann Surg Oncol. 2005 Aug;12(8):646-53 [15965732.001]
  • [Cites] Radiother Oncol. 2005 Apr;75(1):48-53 [15948265.001]
  • [Cites] Ann Oncol. 2004 Nov;15(11):1667-72 [15520069.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):563-72 [9806516.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):197-203 [9440743.001]
  • [Cites] Lancet. 1997 Dec 6;350(9092):1647-54 [9400508.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5):504-14 [9344316.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):977-85 [7607972.001]
  • (PMID = 19577863.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA124557-01A1; United States / NCI NIH HHS / CA / R21 CA124557; United States / NCI NIH HHS / CA / R21 CA124557-01A1
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  • [Other-IDs] NLM/ NIHMS230212; NLM/ PMC2931332
  •  go-up   go-down


18. Barreto-Andrade JC, Medina-Franco H: Serum albumin is an independent prognostic factor for survival in soft tissue sarcomas. Rev Invest Clin; 2009 May-Jun;61(3):198-204
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum albumin is an independent prognostic factor for survival in soft tissue sarcomas.
  • BACKGROUND: Soft tissue sarcomas are rare tumors with a wide clinical spectrum.
  • METHODS: We analyzed a group of 61 patients with soft tissue sarcomas.
  • Adverse prognostic factors for overall survival in multivariate analysis were advanced stage, high tumor grade, irresecability, and serum albumin.
  • Size, high surgical risk (ASA III-IV) and a low performance status (Karnofsky less than 70) were predictive of overall survival only in univariate analysis.
  • CONCLUSIONS: Besides the usual tumor related prognostic factors, such as grade and stage, patient related factors, such as performance status and surgical risk should be considered when predicting survival.
  • [MeSH-major] Sarcoma / blood. Serum Albumin / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers. Cachexia / blood. Cachexia / etiology. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Liposarcoma / blood. Liposarcoma / mortality. Liposarcoma / therapy. Male. Mexico / epidemiology. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19736808.001).
  • [ISSN] 0034-8376
  • [Journal-full-title] Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición
  • [ISO-abbreviation] Rev. Invest. Clin.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Serum Albumin
  •  go-up   go-down


19. Kepka L, Suit HD, Goldberg SI, Rosenberg AE, Gebhardt MC, Hornicek FJ, Delaney TF: Results of radiation therapy performed after unplanned surgery (without re-excision) for soft tissue sarcomas. J Surg Oncol; 2005 Oct 1;92(1):39-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of radiation therapy performed after unplanned surgery (without re-excision) for soft tissue sarcomas.
  • BACKGROUND AND PURPOSE: For soft tissue sarcomas (STS), some patients undergo an "unplanned surgery," non-oncologic resection for presumed benign tumor.
  • Tumor characteristics: location, lower extremity (63%), upper extremity (27%), other (10%); median tumor size, 5 cm; grade-G1 (19%), G2 (49%), G3 (32%); AJCC stage (2002)-I (19%), II (54%), III (27%).
  • Depth in the relation to the fascia, tumor size, and AJCC stage significantly influenced local recurrence- and distant metastasis-free survival.
  • [MeSH-major] Sarcoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Radiotherapy / adverse effects. Radiotherapy Dosage. Retrospective Studies. Survival Analysis. Treatment Failure

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16180232.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. García-Aceituno L, Villarreal-Garza C, Perfecto M, León-Rodríguez E: Retroperitoneal soft tissue sarcomas: experience at a single institution in Mexico. World J Surg; 2010 Jul;34(7):1511-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal soft tissue sarcomas: experience at a single institution in Mexico.
  • BACKGROUND: Retroperitoneal soft tissue sarcomas (RSTS) are a rare and uncommon entity with a poor 5-year overall survival (OS) of approximately 50%, even though they rarely metastasize.
  • Variables analyzed were age, sex, histological type, TNM stage, tumor size, grade of differentiation, and treatment (surgery, chemotherapy only, radiotherapy only, adjuvant radiotherapy, and best supportive care).
  • Overall survival, recurrence-free survival (RFS), cancer-specific survival (CSS), and survival comparison by stage, grade, and type of resection were analyzed.
  • The median CSS for resected patients was 102 months; the 5-year OS for stages I, III, and IV was 83, 37, and 0%, respectively; the 5-year OS for low histological grade disease and high histological grade disease was 82 and 35%, respectively; and for R0, R1, and R2 resection, the 5-year OS was 81, 56, and 14%, respectively.
  • CONCLUSIONS: Incomplete surgical resection, unresectable disease, high histological grade, and advanced TNM stage are associated with a poor survival in patients with RSTS.
  • [MeSH-major] Retroperitoneal Neoplasms / mortality. Sarcoma / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Tomography, X-Ray Computed. Young Adult

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Sarcoma. 2000;4(1-2):17-26 [18521430.001]
  • [Cites] Cancer. 2006 Jul 15;107(2):371-9 [16752414.001]
  • [Cites] Tumori. 2008 Jul-Aug;94(4):497-504 [18822685.001]
  • [Cites] Curr Opin Oncol. 2002 Jul;14(4):400-5 [12130924.001]
  • [Cites] J Clin Oncol. 2009 Jan 1;27(1):31-7 [19047280.001]
  • [Cites] Sarcoma. 2001;5(1):5-8 [18521302.001]
  • [Cites] Ann Surg. 2004 Feb;239(2):244-50 [14745333.001]
  • [Cites] Eur J Surg Oncol. 2009 Sep;35(9):986-93 [19138832.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):164-70 [17084556.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):359-68 [11466691.001]
  • [Cites] J Clin Oncol. 2009 Jan 1;27(1):24-30 [19047283.001]
  • [Cites] N Engl J Med. 2005 Aug 18;353(7):701-11 [16107623.001]
  • [Cites] Chin Med J (Engl). 2007 Jun 20;120(12):1047-50 [17637220.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):508-17 [16491338.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):355-65 [9742918.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2832-9 [9256126.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1610-6 [16518798.001]
  • [Cites] Ann Surg Oncol. 2007 Mar;14(3):1114-22 [17206483.001]
  • [Cites] Cancer. 1994 Feb 1;73(3):637-42 [8299085.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):514-9 [12243830.001]
  • [Cites] Ann Surg Oncol. 1997 Jul-Aug;4(5):421-4 [9259970.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):185-95 [7857146.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):469-75 [11872294.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 30;29(5):1005-10 [8083069.001]
  • [Cites] Eur J Surg Oncol. 2001 Sep;27(6):564-8 [11520090.001]
  • [Cites] Ann Surg Oncol. 2002 May;9(4):346-54 [11986186.001]
  • [Cites] Eur J Surg Oncol. 2001 Aug;27(5):491-7 [11504522.001]
  • (PMID = 20162280.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


21. Leidinger B, Heyse T, Schuck A, Buerger H, Mommsen P, Bruening T, Fuchs S, Gosheger G: High incidence of metastatic disease in primary high grade and large extremity soft tissue sarcomas treated without chemotherapy. BMC Cancer; 2006;6:160
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High incidence of metastatic disease in primary high grade and large extremity soft tissue sarcomas treated without chemotherapy.
  • BACKGROUND: The risk of metastasis and the survival in patients with primary extremity soft tissue sarcomas is worse when tumour size is large and the grade of malignancy is high.
  • METHODS: We retrospectively reviewed the clinical outcome of 233 patients with a primary extremity soft tissue sarcoma treated between 1990 - 2000 with a mean follow-up of 35.8 (4-120) months in our institute.
  • 41 patients had high grade, deep and large tumours (>8 cm), an AJCC stage III (no evidence of metastasis prior to treatment) and were treated with limb salvage surgery and irradiation but stayed without additional chemotherapy.
  • [MeSH-major] Sarcoma / pathology. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis / pathology. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Orthop Scand Suppl. 2001 Feb;72(300):1-31 [11381580.001]
  • [Cites] Radiother Oncol. 2005 Apr;75(1):48-53 [15948265.001]
  • [Cites] Clin Orthop Relat Res. 2002 Apr;(397):177-89 [11953609.001]
  • [Cites] Eur J Surg Oncol. 2002 Jun;28(4):431-6 [12099655.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2235-41 [12103287.001]
  • [Cites] J Clin Oncol. 2002 Nov 15;20(22):4472-7 [12431971.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1117-27 [12829150.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(13):1872-80 [12932665.001]
  • [Cites] Acta Oncol. 2003;42(5-6):516-31 [14596510.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):522-6 [15380587.001]
  • [Cites] Clin Orthop Relat Res. 1980 Nov-Dec;(153):106-20 [7449206.001]
  • [Cites] Ann Surg. 1982 Sep;196(3):305-15 [7114936.001]
  • [Cites] Cancer. 1985 Jun 1;55(11):2659-67 [3995476.001]
  • [Cites] Cancer. 1986 Jan 1;57(1):172-7 [3940616.001]
  • [Cites] Cancer. 1986 Feb 1;57(3):484-91 [3942981.001]
  • [Cites] Cancer. 1986 Jul 15;58(2):306-9 [3719523.001]
  • [Cites] J Clin Oncol. 1987 Mar;5(3):480-8 [3819810.001]
  • [Cites] Cancer. 1987 Oct 1;60(7):1500-4 [3040219.001]
  • [Cites] J Bone Joint Surg Am. 1987 Sep;69(7):1074-8 [3654700.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Apr;14(4):693-9 [3350724.001]
  • [Cites] J Clin Oncol. 1988 May;6(5):854-62 [3367188.001]
  • [Cites] Can J Surg. 1989 Jan;32(1):69-73 [2910383.001]
  • [Cites] Acta Orthop Scand. 1989 Dec;60(6):687-92 [2696323.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):899-906 [2211257.001]
  • [Cites] Ann Surg. 1991 Sep;214(3):328-36; discussion 336-8 [1929613.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Nov;21(6):1485-92 [1938557.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Nov;21(6):1595-9 [1938569.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1992 Jan;4(1):36-43 [1736977.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(3):653-60 [1612967.001]
  • [Cites] Surg Gynecol Obstet. 1993 Feb;176(2):124-34 [8421799.001]
  • [Cites] J Surg Oncol. 1993 Apr;52(4):223-30 [8468983.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1652-9 [8156492.001]
  • [Cites] Eur J Cancer. 1994;30A(6):746-51 [7917531.001]
  • [Cites] J Surg Oncol. 1994 Oct;57(2):111-4 [7934061.001]
  • [Cites] Semin Surg Oncol. 1994 Sep-Oct;10(5):347-56 [7997728.001]
  • [Cites] Acta Orthop Scand. 1994 Oct;65(5):553-8 [7801762.001]
  • [Cites] Cancer. 1995 May 1;75(9):2299-306 [7712441.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):977-85 [7607972.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):869-77 [8622035.001]
  • [Cites] J Surg Oncol. 1996 Feb;61(2):90-9 [8606553.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):197-203 [9440743.001]
  • [Cites] Eur J Cancer. 2001 Sep;37(13):1599-608 [11527684.001]
  • (PMID = 16780601.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1550254
  •  go-up   go-down


22. Naka N, Joyama S, Tsukamoto Y, Yoshioka K, Hashimoto N, Ujiiye T, Hayashi T, Kawase M, Mano M, Ishiguro S, Myoui A, Ueda T, Yoshikawa H, Araki N, Itoh K: Quantification of SSX mRNA expression in human bone and soft tissue tumors using nucleic acid sequence-based amplification. J Mol Diagn; 2005 May;7(2):187-97
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantification of SSX mRNA expression in human bone and soft tissue tumors using nucleic acid sequence-based amplification.
  • We have developed a competitive nucleic acid sequence-based amplification (NASBA) assay to analyze SSX mRNA expression in 211 bone and soft tissue tumors.
  • Further, SSX mRNA expression in stage III tumors was significantly higher than that in stage I or II tumors (P < 0.005).
  • [MeSH-major] Bone Neoplasms / genetics. Neoplasm Proteins / genetics. RNA, Messenger / analysis. Repressor Proteins / genetics. Self-Sustained Sequence Replication. Soft Tissue Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Animals. COS Cells. Child. Female. Gene Expression. Humans. Male. Middle Aged. RNA, Neoplasm / analysis. RNA, Neoplasm / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6223-9 [10626816.001]
  • [Cites] Nucleic Acids Res. 1998 May 1;26(9):2250-1 [9547289.001]
  • [Cites] Lett Appl Microbiol. 2000 Jan;30(1):75-9 [10728566.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1654-62 [10749136.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4499-506 [10969798.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3916-22 [11051238.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12198-203 [11027314.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):629-34 [11149944.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3282-7 [11248070.001]
  • [Cites] J Surg Res. 2001 Jun 15;98(2):76-80 [11397121.001]
  • [Cites] J Immunol. 2002 Feb 15;168(4):1717-22 [11823502.001]
  • [Cites] Int J Cancer. 2002 Apr 1;98(4):640-2 [11920629.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Apr 5;292(3):715-26 [11922625.001]
  • [Cites] Int J Cancer. 2002 Oct 10;101(5):448-53 [12216073.001]
  • [Cites] Immunol Rev. 2002 Oct;188:22-32 [12445278.001]
  • [Cites] Int J Biol Markers. 2002 Oct-Dec;17(4):219-23 [12521124.001]
  • [Cites] Cancer Immun. 2003 Oct 9;3:13 [14533943.001]
  • [Cites] Clin Chim Acta. 2004 Apr;342(1-2):115-26 [15026272.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Clin Orthop Relat Res. 1980 Nov-Dec;(153):106-20 [7449206.001]
  • [Cites] Nature. 1991 Mar 7;350(6313):91-2 [1706072.001]
  • [Cites] Science. 1991 Dec 13;254(5038):1643-7 [1840703.001]
  • [Cites] Nat Genet. 1994 Aug;7(4):502-8 [7951320.001]
  • [Cites] Immunity. 1995 Feb;2(2):167-75 [7895173.001]
  • [Cites] Melanoma Res. 1997 Aug;7 Suppl 2:S83-8 [9578421.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6919-23 [9618514.001]
  • [Cites] Int J Cancer. 1998 Jul 3;77(1):19-23 [9639388.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5211-6 [9560255.001]
  • [Cites] J Bone Joint Surg Am. 1998 Aug;80(8):1204-18 [9730132.001]
  • [Cites] Oncogene. 1998 Oct 15;17(15):2013-8 [9788446.001]
  • [Cites] Int J Cancer. 1999 Jan 18;80(2):219-30 [9935203.001]
  • [Cites] Int J Cancer. 1999 Nov 26;83(5):664-9 [10521804.001]
  • [Cites] EMBO J. 1995 May 15;14(10):2333-40 [7539744.001]
  • [Cites] J Exp Med. 1995 Sep 1;182(3):689-98 [7544395.001]
  • [Cites] Hum Mol Genet. 1995 Jun;4(6):1097-9 [7655467.001]
  • [Cites] Int J Cancer. 1995 Nov 3;63(3):375-80 [7591235.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11810-3 [8524854.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4766-72 [8840996.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1914-8 [9050879.001]
  • [Cites] Int J Cancer. 1997 Sep 17;72(6):965-71 [9378559.001]
  • [Cites] J Exp Med. 1998 Jan 19;187(2):265-70 [9432985.001]
  • [Cites] Int J Cancer. 2000 Mar 1;85(5):726-32 [10699956.001]
  • (PMID = 15858142.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Repressor Proteins; 164289-47-8 / synovial sarcoma X breakpoint proteins
  • [Other-IDs] NLM/ PMC1867521
  •  go-up   go-down


23. Nowecki ZI, Rutkowski P, Kulik J, Siedlecki JA, Ruka W: Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level. Br J Dermatol; 2008 Sep;159(3):597-605
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
  • OBJECTIVES: This study assessed the prognostic value of multimarker reverse transcriptase-polymerase chain reaction (RT-PCR) assay in lymphatic drainage (LY) after lymph node dissection (LND) and of preoperative serum lactate dehydrogenase (LDH) levels in American Joint Committee on Cancer (AJCC) stage III melanoma patients.
  • METHODS: We collected 24-h LY from 255 stage III melanoma patients after radical LND [114, completion LND after positive sentinel node biopsy (CLND); 141, therapeutic LND for clinically/cytologically detected regional nodal metastases (TLND)].
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / genetics. Biomarkers / blood. Disease-Free Survival. Female. Follow-Up Studies. Humans. L-Lactate Dehydrogenase / blood. Lymph Node Excision. Lymphatic Metastasis. MART-1 Antigen. Male. Middle Aged. Monophenol Monooxygenase / genetics. Multivariate Analysis. Neoplasm Proteins / genetics. Neoplasm Staging. Predictive Value of Tests. Proportional Hazards Models. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction / methods. Survival Rate

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18616789.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 1.14.18.1 / Monophenol Monooxygenase
  •  go-up   go-down


24. Demiralp B, Ozdemir MT, Erler K, Basbozkurt M: Type 1 neurofibromatosis and adult extremity sarcoma. A report of two cases. Acta Orthop Belg; 2007 Jun;73(3):403-7
Genetic Alliance. consumer health - Neurofibromatosis type 1.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Type 1 neurofibromatosis and adult extremity sarcoma. A report of two cases.
  • We report two cases of malignant soft-tissue tumours--one myxoid malignant fibrous histiocytoma and one pleomorphic rhabdomyosarcoma--which were diagnosed in two young adult patients with type 1 neurofibromatosis (NF 1).
  • The tumours were stage II and III respectively.
  • Diagnoses of myxoid malignant fibrous histiocytoma and pleomorphic rhabdomyosarcoma in adult NF 1 patients are exceedingly rare.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / complications. Neoplasms, Multiple Primary. Neurofibromatosis 1 / complications. Rhabdomyosarcoma / complications. Soft Tissue Neoplasms
  • [MeSH-minor] Adult. Humans. Male

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17715736.001).
  • [ISSN] 0001-6462
  • [Journal-full-title] Acta orthopaedica Belgica
  • [ISO-abbreviation] Acta Orthop Belg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


25. Guo W, Ji T, Yant Y: [Endoprosthetic reconstruction after wide resection of sarcoma in lower extremities]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2006 Oct;20(10):970-4
MedlinePlus Health Information. consumer health - Bone Grafts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endoprosthetic reconstruction after wide resection of sarcoma in lower extremities].
  • OBJECTIVE: To assess the clinical outcome of the limb salvage surgery and complications occurring in the lower extremities after a wide resection of sarcoma.
  • According to the Enneking staging, 3 patients were grouped in the stage of II A, 85 in I B, and 12 in III.
  • Of the 7 patients, 4 had a recurrence of the soft tissue tumor for which resection was performed; the other 3 patients underwent amputation of the diseased limb.
  • [MeSH-minor] Adolescent. Adult. Female. Follow-Up Studies. Humans. Lower Extremity. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17140065.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


26. Yabe H, Tsukahara T, Kawaguchi S, Wada T, Sato N, Morioka H, Yabe H: Overexpression of papillomavirus binding factor in Ewing's sarcoma family of tumors conferring poor prognosis. Oncol Rep; 2008 Jan;19(1):129-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of papillomavirus binding factor in Ewing's sarcoma family of tumors conferring poor prognosis.
  • Ewing's sarcoma family of tumors (ESFT) is comprised of highly malignant bone and soft tissue tumors in children and young adults.
  • Of the 11 variables analyzed, stage III disease, inadequate surgical margins and PBF overexpression were significantly associated with decreased disease-free and overall survival.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. Bone Neoplasms / metabolism. Bone Neoplasms / pathology. Sarcoma, Ewing / metabolism. Sarcoma, Ewing / pathology
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Immunohistochemistry. Infant. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097586.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / osteosarcoma-associated antigen
  •  go-up   go-down


27. Blazer DG 3rd, Lazar AJ, Xing Y, Askew RL, Feig BW, Pisters PW, Pollock RE, Lev D, Hunt KK, Cormier JN: Clinical outcomes of molecularly confirmed clear cell sarcoma from a single institution and in comparison with data from the Surveillance, Epidemiology, and End Results registry. Cancer; 2009 Jul 1;115(13):2971-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcomes of molecularly confirmed clear cell sarcoma from a single institution and in comparison with data from the Surveillance, Epidemiology, and End Results registry.
  • BACKGROUND: The authors compared disease-specific survival (DSS) in stage-specific subgroups of patients with clear cell sarcoma, including those with lymph node metastases (N1M0) and those with distant metastases (N0M1).
  • METHODS: Clinical data regarding soft tissue sarcoma patients were obtained from The University of Texas M. D.
  • When possible, clear cell sarcoma diagnoses were confirmed using fluorescence in situ hybridization or reverse-transcription polymerase chain reaction.
  • RESULTS: Fifty-two patients at MDACC and 130 SEER patients were diagnosed with clear cell sarcoma.
  • After adjustment, the hazards ratio (HR) for dying was 2.79 for N1M0 disease (95% confidence interval [95% CI], 1.32-5.91) and 11.37 (95% CI, 5.19-24.91) for N0M1 disease compared with stage II disease (P < .001).
  • CONCLUSIONS: The findings of the current study suggest that patients with N1M0 clear cell sarcoma have 5-year DSS that is more similar to that of patients with stage III than stage IV soft tissue sarcoma.
  • [MeSH-major] Sarcoma / genetics. Sarcoma / pathology. Sarcoma, Clear Cell / genetics. Sarcoma, Clear Cell / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis. SEER Program. Young Adult

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19402173.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Zivanovic O, Leitao MM, Iasonos A, Jacks LM, Zhou Q, Abu-Rustum NR, Soslow RA, Juretzka MM, Chi DS, Barakat RR, Brennan MF, Hensley ML: Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on cancer staging systems. J Clin Oncol; 2009 Apr 20;27(12):2066-72
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on cancer staging systems.
  • We aimed to determine whether the American Joint Committee on Cancer (AJCC) soft tissue sarcoma (STS) staging system is more accurate in predicting progression-free survival (PFS) and overall survival (OS).
  • Stage-specific PFS and OS rates for stages I, II, and III differed substantially between the two staging systems.
  • In both systems, there was prognostic overlap between stages II and III.
  • Thus, despite the marked stage-specific differences in 5-year PFS and OS rates for stages I, II, and III, both systems had similar concordance indices.
  • CONCLUSION: Estimates of stage-specific PFS and OS for uterine LMS were altered substantially when using the AJCC versus FIGO staging system.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. International Agencies. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Prognosis. Risk Factors. Survival Rate

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Obstet Gynecol. 2008 Apr;198(4):457.e1-5; discussion 457.e5-6 [18395039.001]
  • [Cites] Am J Obstet Gynecol. 1979 Jul 1;134(5):557-64 [453295.001]
  • [Cites] Int J Oncol. 2008 May;32(5):1111-7 [18425339.001]
  • [Cites] N Engl J Med. 1985 Jun 20;312(25):1604-8 [4000199.001]
  • [Cites] J Clin Oncol. 1985 Sep;3(9):1240-5 [3897471.001]
  • [Cites] J Natl Cancer Inst. 1986 Mar;76(3):399-402 [3456457.001]
  • [Cites] Am J Obstet Gynecol. 1987 Mar;156(3):660-2 [3826216.001]
  • [Cites] Obstet Gynecol. 1988 Jun;71(6 Pt 1):845-50 [2453004.001]
  • [Cites] World J Surg. 1988 Jun;12(3):326-31 [3400243.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):35-9 [2354406.001]
  • [Cites] Ann Intern Med. 1991 Dec 1;115(11):906-7 [1952481.001]
  • [Cites] Cancer. 1993 Feb 15;71(4 Suppl):1702-9 [8381710.001]
  • [Cites] Gynecol Oncol. 1993 Jul;50(1):105-9 [8349151.001]
  • [Cites] Am J Surg Pathol. 1994 Jun;18(6):535-58 [8179071.001]
  • [Cites] Obstet Gynecol. 1994 Jun;83(6):1015-20 [8190416.001]
  • [Cites] Acta Oncol. 1995;34(6):797-802 [7576748.001]
  • [Cites] Stat Med. 1996 Feb 28;15(4):361-87 [8668867.001]
  • [Cites] Gynecol Oncol. 1996 Jul;62(1):25-32 [8690287.001]
  • [Cites] Gynecol Oncol. 1999 Aug;74(2):196-201 [10419731.001]
  • [Cites] Stat Med. 1999 Sep 15-30;18(17-18):2529-45 [10474158.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):163-71 [16331596.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3819-20 [16864852.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3967-72 [16864855.001]
  • [Cites] J Clin Oncol. 2007 Apr 10;25(11):1316-22 [17416852.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4679-85 [17299097.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3576-81 [17704404.001]
  • [Cites] Cancer. 2008 Feb 15;112(4):820-30 [18189292.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1425-31 [10717626.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):791-6 [11821462.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2824-31 [12065559.001]
  • [Cites] Curr Opin Urol. 2003 Mar;13(2):111-6 [12584470.001]
  • [Cites] Gynecol Oncol. 2003 Jun;89(3):460-9 [12798712.001]
  • [Cites] Gynecol Oncol. 2003 Oct;91(1):209-12 [14529683.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):648-52 [14766261.001]
  • [Cites] Stat Med. 2004 Mar 15;23(5):723-48 [14981672.001]
  • [Cites] J Clin Oncol. 2004 Sep 15;22(18):3668-76 [15302909.001]
  • [Cites] Eur J Cancer. 2008 Apr;44(6):808-18 [18378136.001]
  • (PMID = 19255317.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3646302
  •  go-up   go-down


29. Gürkan V, Ozger H: [Sarcomas of the hand]. Acta Orthop Traumatol Turc; 2007 Aug-Oct;41(4):286-90
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated patients who underwent surgical treatment for sarcoma of the hand.
  • METHODS: Between 1990 and 2006, eight patients (5 males, 3 females; mean age 39.6 years; range 26 to 67 years) with hand sarcoma received treatment at two centers.
  • The lesions arose from soft tissue in five cases, and from bone in three cases.
  • RESULTS: Mortality occurred in two patients due to multiple metastases, who had synovial sarcoma in the carpal region and clear cell sarcoma in the wrist, respectively.
  • Both patients had stage III disease on presentation.
  • Of three patients with tumors localized in the fingers, two had stage IA, and one had stage IB disease.
  • Apart from clear cell sarcoma, diagnoses of other wrist tumors were stage IIB epithelioid sarcoma and malignant fibrous histiocytoma.
  • [MeSH-major] Hand. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Severity of Illness Index. Treatment Outcome. Turkey / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18180558.001).
  • [ISSN] 1017-995X
  • [Journal-full-title] Acta orthopaedica et traumatologica turcica
  • [ISO-abbreviation] Acta Orthop Traumatol Turc
  • [Language] tur
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


30. Turcotte RE, Ferrone M, Isler MH, Wong C: Outcomes in patients with popliteal sarcomas. Can J Surg; 2009 Feb;52(1):51-5
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Soft-tissue sarcoma involving the popliteal fossa remains challenging because it is difficult to achieve wide margins with limb salvage in this location.
  • Frequent histologic diagnoses were liposarcoma (n = 6), synovial sarcoma (n = 4) and leiomyosarcoma (n = 3).
  • American Joint Committee on Cancer staging was as follows: 4 patients had stage IIa disease, 3 patients had stage IIb, 10 patients had stage III and 1 patient had stage IV disease.
  • [MeSH-major] Knee. Outcome Assessment (Health Care). Sarcoma / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Amputation / statistics & numerical data. Chemotherapy, Adjuvant. Databases, Factual. Female. Humans. Limb Salvage. Lung Neoplasms / secondary. Male. Middle Aged. Prospective Studies. Radiotherapy, Adjuvant. Retrospective Studies. Sciatic Nerve / surgery. Surgical Wound Dehiscence / etiology. Surgical Wound Infection / etiology. Thrombophlebitis / etiology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 2000 Apr;73(4):206-11 [10797333.001]
  • [Cites] Eur J Surg Oncol. 2007 May;33(4):512-7 [17174515.001]
  • [Cites] Acta Orthop Scand. 2001 Apr;72(2):160-6 [11372947.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2235-41 [12103287.001]
  • [Cites] Ann Surg Oncol. 2004 May;11(5):476-82 [15078635.001]
  • [Cites] Ann Surg. 1968 Jul;168(1):47-53 [4299767.001]
  • [Cites] J Bone Joint Surg Am. 1980 Sep;62(6):1027-30 [7000786.001]
  • [Cites] Cancer. 1981 Mar 1;47(5):1005-22 [7226034.001]
  • [Cites] Cancer. 1986 Apr 15;57(8):1632-9 [3948134.001]
  • [Cites] Clin Orthop Relat Res. 1986 Mar;(204):9-24 [3456859.001]
  • [Cites] Acta Orthop Scand. 1987 Oct;58(5):516-22 [3425281.001]
  • [Cites] Cancer. 1988 Feb 15;61(4):817-23 [3338039.001]
  • [Cites] Cancer. 1989 Apr 1;63(7):1437-51 [2646010.001]
  • [Cites] J Bone Joint Surg Am. 1989 Mar;71(3):370-5 [2925710.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):899-906 [2211257.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Nov;21(6):1493-9 [1938558.001]
  • [Cites] J Surg Oncol. 1993 Apr;52(4):223-30 [8468983.001]
  • [Cites] Clin Orthop Relat Res. 1993 Apr;(289):19-31 [8472413.001]
  • [Cites] Clin Orthop Relat Res. 1993 Apr;(289):73-80 [8472434.001]
  • [Cites] Eur J Cancer. 1994;30A(6):746-51 [7917531.001]
  • [Cites] Cancer. 1995 Oct 15;76(8):1398-405 [8620414.001]
  • [Cites] Curr Probl Surg. 1996 Oct;33(10):817-72 [8885853.001]
  • [Cites] Qual Life Res. 1996 Oct;5(5):508-16 [8973131.001]
  • [Cites] Clin Orthop Relat Res. 1999 Jan;(358):90-100 [9973980.001]
  • [Cites] Radiother Oncol. 2005 Apr;75(1):48-53 [15948265.001]
  • [Cites] Clin Orthop Relat Res. 2007 Feb;455:225-33 [16957647.001]
  • [Cites] Surg Oncol. 1999 Dec;8(4):211-4 [11128835.001]
  • (PMID = 19234652.001).
  • [ISSN] 1488-2310
  • [Journal-full-title] Canadian journal of surgery. Journal canadien de chirurgie
  • [ISO-abbreviation] Can J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2637647
  •  go-up   go-down


31. Rutkowski P, Nowecki ZI, Zdzienicki M, Michej W, Symonides M, Rosinska M, Dziewirski W, Bylina E, Ruka W: Cutaneous melanoma with nodal metastases in elderly people. Int J Dermatol; 2010 Aug;49(8):907-13
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We analyzed data from 849 consecutive patients with stage III cutaneous melanoma who were treated between 1994 and 2007 at one institution.
  • Independent negative prognostic factors of DSS in the group of older stage III patients were identified as features of nodal metastases (extracapsular invasion, HR = 1.74, P = 0.009; and ≥ 4 involved lymph nodes, HR = 1.5; P = 0.008) and male sex (HR = 1.5; P = 0.039).
  • CONCLUSIONS: This analysis showed that melanoma patients ≥ 65 years of age are characterized by a higher primary tumor stage and worse prognosis in the presence of regional node metastases than younger patients.
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Incidence. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Prognosis. Sex Distribution. Young Adult

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The International Society of Dermatology.
  • (PMID = 21174374.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Rutkowski P, Nowecki ZI, Dziewirski W, Zdzienicki M, Pieñkowski A, Salamacha M, Michej W, Trepka S, Bylina E, Ruka W: Melanoma without a detectable primary site with metastases to lymph nodes. Dermatol Surg; 2010 Jun;36(6):868-76
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We included data from 459 consecutive patients treated from 1994 to 2007 with radical therapeutic lymph node dissection (LND; stage IIIB, C) due to clinically palpable and pathologically confirmed lymph node metastases (229 axillary; 230 ilioinguinal).
  • Thus, all MUP cases should be treated as standard stage III melanomas.
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20482725.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Nowecki ZI, Rutkowski P, Michej W: The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3). Ann Surg Oncol; 2008 Aug;15(8):2223-34
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of our study was to assess the overall survival (OS; calculated both from the date of primary tumor excision and lymph node dissection) data from two large groups of AJCC 2002 stage-III cutaneous melanoma patients-after completion lymph node dissection (CLND after positive sentinel node biopsy) and after therapeutic LND (TLND for clinically/cytologically detected regional lymph node metastases).
  • [MeSH-minor] Adult. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Survival Rate

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18506535.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Rutkowski P, Nowecki ZI, Kulik J, Ruka W, Siedlecki JA: Molecular staging by multimarker reverse transcriptase-polymerase chain reaction assay of lymphatic drainage and blood from melanoma patients after lymph node dissection. Melanoma Res; 2008 Aug;18(4):246-52
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We collected 24-h lymph fluid (LY) and peripheral blood (BL) from 107 stage III melanoma patients after radical LND (59 axillary and 48 ilioinguinal LND).
  • The LY MM RT-PCR seems to be an effective prognostic tool for stage III melanoma patients.
  • [MeSH-minor] Adult. Aged. Disease Progression. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplastic Cells, Circulating. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Skin Neoplasms / blood. Skin Neoplasms / mortality. Skin Neoplasms / pathology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18626308.001).
  • [ISSN] 1473-5636
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down






Advertisement